Klebsiella is the leading cause of pneumonia, which is now the No. 1 killer in Malaysia with over 18,000 deaths reported in 2023. Fortunately, there is now an effective weapon in the market to effectively prevent and fight this deadly disease. SIM01 has been proven to greatly enhance short-chain fatty acids (SCFAs) in our body to combat viral infections.
How Does SIM01 Boost SCFAs In The Body?
Bacteria in the gut use a molecule called pyruvate to produce SCFAs. Pyruvate is produced through the breakdown of carbohydrates, or glucose, during glycolysis (the process in which glucose is broken down to produce energy).
Pyruvate serves as a precursor to produce amino acids, fatty acids, and other biomolecules critical for cell structure, growth, and function. SIM01 boosts the production of SCFAs in the gut by increasing the activity of three important pathways that use pyruvate to make SCFAs:
- Making acetone from pyruvate.
- Making butanoate from pyruvate.
- Making acetate and lactate from pyruvate: this pathway also produces SCFAs [1].
The SCFA Effect: Reducing Klebsiella and Fighting Antibiotic Resistance
Antibiotic resistance rates have been increasing in Malaysia due largely to the uncontrolled and indiscriminate dispensing of antibiotics by medical practitioners. The National Medical Care Survey (NMCS) found that 30.8% of antibiotic prescriptions were in private clinics, compared to 6.8% in public clinics.
From 2022 until 2023, Malaysia’s MRSA’s (Methicillin-Resistant Staphylococcus Aureus– a group of gram-positive bacteria) resistance rate was 45%, which is higher than the global benchmark of 30% [2], truly a cause for great concern.
Clearly, to win the war against the antibiotic-resistant Klebsiella Pneumoniae, radical measures are required. This is where SIM01 has the upper hand compared to all other solutions in the market.
SIM01’s Proven Efficacy
The effectiveness of SIM01 has been proven in 5 crucial areas. In a clinical trial, it was found that SIM01 with its SCFA-enhancing effects:
- Increased SCFAs: SIM01 increases the production of SCFAs in our body which exerts anti-inflammatory effects and helps repair and protect our gut barrier.
- Reduced Klebsiella Pneumoniae: SIM01 helps restore gut dysbiosis (imbalance). This reduces the levels ofKlebsiella Pneumoniae in our body and increases the levels of SCFAs in our system.
- Reduced Antibiotic Resistance: SIM01 also significantly reduces antimicrobial resistance genes (ARGs) in our gut. ARGs enable bacteria, viruses, fungi, or parasites to survive even when exposed to medications designed to kill them. These ARGs can be transferred between microbes through horizontal gene transfer (HGT), contributing to the spread of drug resistance and leading to secondary infections that are difficult or impossible to treat with antibiotics. SIM01 is equally effective whether it is consumed during the virus-positive period or after the virus is cleared.
- Ensured Long-Term Effects: The reduction in ARGs lasts for up to 12 weeks after stopping SIM01, which makes it a very viable treatment option ensuring long-lasting results.
- Impacted Gut Health: By restoring gut microbiota balance, SIM01 helps people overcome antibiotic resistance, providing a long-term solution for patients recovering from COVID-19 or influenza.
In short, flu or Covid-19 infections can lead to increased Klebsiella Pneumoniae in the body which then leads to increased ARGs, ultimately causing Long Covid symptoms and serious secondary infections.
Consuming SIM01 has been proven to reduce Klebsiella Pneumoniae which then leads to reduced ARGs which further leads to reduced side effects and secondary infections.
Beware: Some Probiotics in the Market Carry Antimicrobial Resistance Genes (ARGs)
Before you rush out to grab your probiotics, however, be warned that not all probiotics are the same. Some probiotics may actually be ARG carriers that contain genes that make them resistant to antibiotics.
These ARG genes can be transferred to harmful bacteria in the gut, contributing to antibiotic resistance and potential secondary infections [3].
Double Assurance For Complete Peace of Mind
Only SIM01 has been clinically proven to be both safe by significantly reducing ARGs, and effective in increasing SCFAs.
Beyond Klebsiella: The Broader Benefits of SCFA-Boosting
Eradicating Long Covid Symptoms
The good news is that SIM01 doesn’t just help prevent and fight pneumonia by promoting a robust gut microbiome rich in SCFAs. Studies have shown that SCFAs are also excellent for alleviating the lingering effects of Long Covid. Many people still battle with Long Covid symptoms such as fatigue, brain fog, joint pains and digestive issues, weeks or even months, after their initial Covid infection.
In a clinical trial, significant improvements were observed in various symptoms of post-acute COVID-19 syndrome (PACS) among patients treated with SIM01. The randomized, double-blind, placebo-controlled trial involved 463 patients and showed that SIM01 significantly improved multiple PACS symptoms compared to those in the placebo group, after 6 months [4].
In particular, people who received SIM01 experienced great improvements in their lung function. Coughing improved by 79% and shortness of breath improved by 68%. Without a doubt, regular consumption of SIM01 will help your body recover from the long-term effects of viral infections.
SCFA-boosting SIM01 has also been proven to enhance overall health and wellness. SCFAs provide these additional health benefits, such as:
- Improved Mood: SCFAs can improve mood, cognitive function and mental well-being by influencing the Gut-Brain Axis, reducing inflammation, regulating neurotransmitter production like serotonin, and interacting with the Vagus Nerve, which directly sends signals between the gut and the brain.
- Enhanced Immune Function: SCFAs enhance immunity by directly interacting with immune cells in the gut like macrophages, neutrophils, dendritic cells, and T lymphocytes to reduce inflammation, stop infections, and regulate immune responses.
- Better Digestive Health: SCFAs improve digestive health by energizing colon cells, maintaining the integrity of the intestinal barrier, increasing gut motility (movement), and promoting the growth of beneficial gut bacteria.
A Ground-Breaking, Game-Changing Discovery About SFCAs
The latest study and review in Trends in Microbiology and ground-breaking research from The Chinese University of Hong Kong (CUHK) revealed an astounding SCFA-Flu Connection. SCFAs can significantly boost immunity against influenza and other viral infections.
The key findings from the Study were:
- SCFAs produced by gut probiotics can reduce viral loads and enhance vaccine efficacy.
- A high-fiber diet and a healthy gut microbiome are essential for producing natural SCFAs, and
- SCFAs help combat various viral infections, including influenza and COVID-19 [5].
Conclusion: A New Weapon in the Fight Against Respiratory Infections
Be encouraged! The much-feared Klebsiella Pneumoniae will no longer cause you nightmares thanks to SIM01, your powerful ally and trusted superhero by your side and at your command!
SIM01’s extraordinary ability to increase pathogen-fighting SCFAs in your gut is the key to combating respiratory infections, especially potentially-fatal Pneumonia caused by the Klebsiella bacterium.
Ready to take control of your gut and lung health? Protect yourself and your family by increasing the SCFAs in your body. Get your SIM01 today at your nearest Pharmacy and start experiencing an unprecedented level of health and wellness!
References:
[1] Lau, Raphaela, A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial, The Lancet Infectious Diseases, Volume 24, Issue 3, 256 – 265.
[2] Bhatt V, Ponnampalavanar SSS, Chong CW, Tang LY, Krishnasamy K, Goh SSL, Teh CSJ. Socio-Demographic Factors and Public Knowledge of Antibiotic Resistance. Healthcare (Basel). 2023 Aug 14;11(16):2284.
[3] Su Q. Antibiotics and probiotics impact gut antimicrobial /a resistance gene reservoir in COVID-19 patients. Gut Microbes. 2022 Jan-Dec;14(1):2128603
Tóth AG. Antimicrobial Resistance Genes in Probiotics. Antibiotics (Basel). 2021 Oct 21;10(11):128.
[4] Recovery Study (The Lancet Infectious Diseases), R.I. Lau et al. Lancet Infect Dis 2023. A symbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. [5] CUHK Press Release: https://lnkd.in/g8N-wYBT